Navigation Links
Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
Date:10/30/2013

CAMBRIDGE, Mass., Oct. 30, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results of a global, Phase 2, open-label, randomized study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.

This study did not meet the primary endpoint of progression free survival in the overall population.  The hazard ratio (HR) for progression free survival (PFS) was 1.0 [95% CI 0.74 - 1.4].

Ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a potential subpopulation of patients benefiting from MM-121 treatment in combination with paclitaxel. When using a combination of two biomarkers, the hazard ratio for PFS was 0.37 [95% CI 0.2 - 0.8] in the 34% of patients who were biomarker positive. The hazard ratio for PFS in the biomarker negative population was 1.54 [95% CI 1.0 - 2.4].

An overall increase in all grades of gastrointestinal toxicities, including diarrhea (73.6% vs. 42.5%), vomiting (31.4% vs. 18.8%) and other mucosal toxicities such as rhinitis (7.1% vs. 1.3%), epistaxis (23.6% vs. 17.5%), stomatitis (22.1% vs. 10.0%) and mucosal inflammation (22.1% vs. 1.3%), were observed in the combination as compared to paclitaxel alone, the majority of which were mild to moderate in severity. An increase in the pulmonary embolism rate was observed with the combination of MM-121 and paclitaxel (5.0% vs. 1.2%). No enhancement of paclitaxel-related peripheral neuropathy was reported with the combination.

"This unique study design lays the groundwork for future translational studies in ovarian cancer. The rapid enrollment into this study was a testament to the commitment of patients and physicians to advance our knowledge and improve upon available therapies i
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
4. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
5. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
6. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
7. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
8. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
9. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
10. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
11. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Leading ... to capture critical product and market insights in ... benefits to employee-based studies, it is essential for ... own internal employees to capture critical business-related insights. ... benchmarking firm, Best Practices, LLC, most benchmarked companies ...
(Date:7/2/2015)... , July 2, 2015 /PRNewswire/ - ESSA Pharma Inc. ... common shares have been approved for listing and trading on ... ESSA will begin trading on NASDAQ on July 9, ... Venture Exchange under the symbol "EPI". As a ... NASDAQ, each of the Company,s outstanding special warrants issued on ...
(Date:7/2/2015)... July 2, 2015 ResMed Inc. (NYSE: RMD ... and fiscal year ended June 30, 2015 results on Thursday, ... close. A press release with ResMed,s results will be issued ... host a webcast to discuss operating results and future outlook. ... 1:30 p.m. US Pacific Time and the live webcast of ...
Breaking Medicine Technology:Leveraging Employee Insights to Produce Cutting-Edge Market Research 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2
... SARcode Bioscience, Inc., a privately-held biopharmaceutical company, ... enrolled in the company,s pivotal Phase 3 clinical ... (Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO) SAR 1118 ... by blocking the binding of two key cellular ...
... response to the growing needs of its clients, Avrio ... Hull 72FXS100-SS25C Freeze Drying System and a new M&O ... Alu-Crimp Capping Machine. The acquisition of these leading-edge technologies ... and Bosch FLT Automated Filling/Stoppering/Capping systems allow Avrio to ...
Cached Medicine Technology:First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution 2First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution 3Avrio Purchases a New Lyophilizer and Liquid Vial Filling Machine - New Capabilities and Added Capacity 2
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... located in the Lone Star State. The premium frozen yogurt chain was listed as ... store, which opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy ...
(Date:7/2/2015)... ... ... Following the recent report by JAMA Internal Medicine published on June ... Becic emphatically declared a war on obesity in the United States. , "Obesity is ... understand the magnitude of this discovery. For that reason, I am declaring, along with ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... (D-Md.) for her introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 ... Jack Reed (D-R.I.), this Act seeks to decrease drug overdose – especially of ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the parking structure retrofit project at the University of Minnesota, they knew it ... that it would also be an award-winning choice: the total energy savings after ...
(Date:7/2/2015)... ... July 02, 2015 , ... Many Fourth of July celebrations will include ... Amica Insurance is sharing some tips to promote the proper use of fireworks. ... to the emergency room daily with fireworks-related injuries in the month surrounding the Fourth ...
Breaking Medicine News(10 mins):Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:6 Fireworks Safety Tips from Amica Insurance 2
... acidity of stomach contents backwashed into the esophagus allows ... throat discomfort// associated with the conventional wired monitor used ... while the new technology appears be better tolerated, no ... managing these patients, said David Mark, M.D., lead author ...
... of women in the Nurses' Health Study has shown that ... (POAG), the most common form of glaucoma//, accounting for about ... in the July issue of the journal Ophthalmology. ... Women's ,Hospital, Harvard School of Public Health and Harvard Medical ...
... A new report has revealed that U.S. emergency medical ... to handle disasters. The need of the hour is ... improve coordination before and after patients arrive. ... of Sciences' Institute of Medicine (IOM) have pointed out ...
... research has revealed that age-related macular degeneration (AMD) is twice ... also found // that those among the elderly who ate ... to have AMD than those who eat fish less than ... by Johanna Seddon, MD, and colleagues who work at the ...
... sleep would probably help the human brain to enhance memories ... ,It was reported that previous studies had established the benefits ... to tap numeric sequences on a keyboard. It was explained ... those used for recalling the facts for a test, where ...
... of General Psychiatry, says that obese people are not jolly ... on more than 9,000 adults found that obese persons were ... anxiety disorders including, depression. ,"Understanding the connection between ... both of these conditions are so common and have a ...
Cached Medicine News:Health News:New Reflux Disease Technology More Comfortable, Not More Effective 2Health News:New Reflux Disease Technology More Comfortable, Not More Effective 3Health News:Type 2 Diabetes Increases the Risk of Glaucoma in Women 2Health News:US Emergency Rooms ill prepared for Disasters 2Health News:Save your Vision with Fish Oil and Quitting Smoking 2Health News:Sleep Essential For A Strong Memory 2
... with elastic fabric, these head cap systems ... to begin testing. Each Electro-Cap System features ... International 10-20 System. When you place your ... using with your head cap system and ...
... head cap systems are packaged to provide ... Electro-Cap System features pure tin electrodes positioned ... you place your order, please specify which ... cap system and whether you want regular ...
... OR, ER, or ICU, be sure you take ... Keeping noise low and signal quality high, each ... special shielded cable that insulates the recording lead ... That means you get a cleaner, quieter signaleven ...
... The Bio-eye hydroxyapatite (HA) orbital implant ... in the early 1980s, after a comprehensive ... which included the earliest manuscripts dating back ... with an ongoing dissatisfaction with the performance ...
Medicine Products: